A Physicochemical Approach for Predicting the Effectiveness of Peptide-Based Gene Delivery Systems for Use in Plasmid-Based Gene Therapy  by Duguid, John G. et al.
A Physicochemical Approach for Predicting the Effectiveness of Peptide-
Based Gene Delivery Systems for Use in Plasmid-Based Gene Therapy
John G. Duguid,* Cynthia Li,* Mei Shi,* Mark J. Logan,* Hector Alila,* Alain Rolland,* Eric Tomlinson,*
James T. Sparrow,# and Louis C. Smith#
*GeneMedicine, The Woodlands, Texas 77381-4248, and #Department of Medicine, Baylor College of Medicine,
Houston, Texas 77030-2707 USA
ABSTRACT Novel synthetic peptides, based on carrier peptide analogs (YKAKnWK) and an amphipathic peptide (GLFEA-
LLELLESLWELLLEA), have been formulated with DNA plasmids to create peptide-based gene delivery systems. The carrier
peptides are used to condense plasmids into nanoparticles with a hydrodynamic diameter (DH) ranging from 40 to 200 nm,
which are sterically stable for over 100 h. Size and morphology of the carrier peptide/plasmid complex have been determined
by photon correlation spectroscopy (PCS) and transmission electron microscopy (TEM), respectively. The amphipathic
peptide is used as a pH-sensitive lytic agent to facilitate release of the plasmid from endosomes after endocytosis of the
peptide/plasmid complex. Hemolysis assays have shown that the amphipathic peptide destabilizes lipid bilayers at low pH,
mimicking the properties of viral fusogenic peptides. However, circular dichroism studies show that unlike the viral fusion
peptides, this amphipathic peptide loses some of its -helical structure at low pH in the presence of liposomes. The
peptide-based gene delivery systems were tested for transfection efficiency in a variety of cell lines, including 14-day C2C12
mouse myotubes, using gene expression systems containing the -galactosidase reporter gene. Transfection data demon-
strate a correlation between in vitro transfection efficiency and the combination of several physical properties of the
peptide/plasmid complexes, including 1) DNA dose, 2) the zeta potential of the particle, 3) the requirement of both lytic and
carrier peptides, and 4) the number of lysine residues associated with the carrier peptide. Transfection data on 14-day C2C12
myotubes utilizing the therapeutic human growth hormone gene formulated in an optimal peptide gene delivery system show
an increase in gene expression over time, with a maximum in protein levels at 96 h (18 ng/ml).
INTRODUCTION
Among several methods of gene transfer, including cell-
based and viral-mediated approaches, nonviral gene deliv-
ery is becoming a major focus of research in the field of
gene therapy (Ledley, 1994, 1995; Rolland, 1996, 1997;
Rolland and Tomlinson, 1996; Tomlinson and Rolland,
1996). This increased interest in nonviral gene therapy can
be attributed to promising results both, in vitro and in vivo,
in delivering genes using proteins (Cotten et al., 1990, 1993;
Plank et al., 1992; Trubetskoy et al., 1992; Wagner et al.,
1990, 1991, 1992; Wang and Huang, 1989; Wu and Wu,
1987, 1988a,b), high-molecular-weight polypeptides (Cot-
ten et al., 1990; Erbacher et al., 1995; Midoux et al., 1993;
Monsigny et al., 1994; Wagner et al., 1990, 1991), cationic
lipids and liposomes (Dowty and Wolff, 1994; Felgner et
al., 1987; Legendre and Szoka, 1992; Trubetskoy et al.,
1992; Wang and Huang, 1989), novel synthetic polymers
(Boussif et al., 1995; Haensler and Szoka, 1993; Kabanov
and Kabanov, 1995), or combinations thereof (Plank et al.,
1994; Remy et al., 1995; Trubetskoy et al., 1992; Wagner et
al., 1991; Zhou et al., 1991). The utilization of many of
these delivery systems stems from their ability to interact
with a plasmid and self-assemble into compact particles
(Bloomfield et al., 1992; Chattoraj et al., 1978; Evdokimov
et al., 1973, 1976; Ghirlando et al., 1992; Gosule and
Schellman, 1976; Haynes et al., 1970; Hirschman et al.,
1967; Laemmli, 1975; Lerman, 1971; Olins et al., 1967;
Shapiro et al., 1969; Widom and Baldwin, 1980, 1983;
Wilson and Bloomfield, 1979). Some polymers have been
conjugated to targeting ligands for cell-specific gene deliv-
ery, resulting in enhanced gene transfer efficiency via the
route of receptor-mediated endocytosis (Cotten et al., 1993;
Erbacher et al., 1995; Gottschalk et al., 1993; Midoux et al.,
1993; Monsigny et al., 1994; Plank et al., 1992; Wagner et
al., 1990, 1991; Wu and Wu, 1987, 1988a,b). Endosomo-
lytic agents are regularly introduced into the gene delivery
system to prevent lysosomal plasmid degradation and sub-
sequently improve the translocation of a plasmid to the
nucleus of a target cell (Fattal et al., 1994; Gottschalk et al.,
1996; Haensler and Szoka, 1993; Legendre and Szoka,
1993; Parente et al., 1990a,b; Plank et al., 1994; Subbarao et
al., 1987; Wagner et al., 1992).
Most of the polypeptide gene delivery systems present a
heterogeneous, high-molecular-weight component. Such
macromolecules, which are generally highly charged, have
a propensity to elicit an immune response and are often
cytotoxic. In addition, it has been suggested that biologi-
cally active regions of many proteins consist of residues that
are only 10–20 amino acids in length (Gottschalk et al.,
1996). The use of high-molecular-weight polypeptides may
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not be necessary, because it has been shown that low-
molecular-weight counterions with more than two positive
charges are capable of inducing DNA condensation into
compact structures (Bloomfield et al., 1992; Chattoraj et al.,
1978; Gosule and Schellman, 1976; Widom and Baldwin,
1980, 1983; Wilson and Bloomfield, 1979). In one instance
it has been shown that a divalent transition-metal cation is
capable of condensing DNA (Ma and Bloomfield, 1994).
Whereas the packaging of DNA into condensed particles
has been studied extensively (Bloomfield, 1992; Bloomfield
et al., 1980; Duguid and Bloomfield, 1996; Eickbush and
Moudrianakis, 1978; Hud, 1995; Hud et al., 1995; Li et al.,
1991; Manning, 1980, 1981, 1985; Post and Zimm, 1979,
1982a,b; Richards et al., 1973), only recently have attempts
been made to identify the properties of the condensed plas-
mid that influence transfection efficiency (Bloomfield,
1996; Tang and Szoka, 1997). Several such attempts have
focused primarily on lipid and liposome-based condensed
systems (Gao and Huang, 1995; Gershon et al., 1993;
Gustafsson et al., 1995; Labat-Moleur et al., 1996; Ra¨dler et
al., 1997; Reimer et al., 1995; Smith et al., 1993; Sternberg
et al., 1994).
In this publication we describe the correlation between
some of the physical characteristics of a peptide/plasmid
gene delivery system and its ability to transfect cells in
vitro. Short oligolysine peptides (GM208-GM240) with the
sequence YKA(K)nWK, where n  4–8, 12, and 40, have
been synthesized (Gottschalk et al., 1996). The effects of
their interactions with plasmids on particle size has been
analyzed as a function of peptide/DNA charge ratio, number
of lysine residues, DNA concentration, and time. An am-
phipathic, pH-sensitive peptide (GM225.1) with the se-
quence GLFEALLELLESLWELLLEA has been incorpo-
rated into the peptide/plasmid complex to effect
intracellular trafficking of the peptide-gene delivery system
(Gottschalk et al., 1996). The endosomolytic peptide
GM225.1 is shown to be membrane active at pH 5.0 but not
at pH 7.4. This pH-dependent lytic activity prevents damage
to the plasma membrane, while inducing modification of the
endosomal membrane, thus enabling plasmids to be re-
leased from endosomes into the cytoplasm.
The peptide-based gene delivery systems were tested for
transfection efficiency in a variety of cell lines, including
RAW264.7 mouse macrophages, HIG-82 rabbit synovio-
cytes, and C2C12 mouse myotubes, by use of a gene expres-
sion system containing the -galactosidase reporter gene.
The necessity of both carrier and lytic peptide for effective
gene transfer was assessed. Physicochemical properties of
the delivery systems were simultaneously analyzed (e.g.,
pH, particle size, and zeta potential). Transfection efficiency
in 14-day C2C12 myotubes was also tested as a function of
the number of lysine residues in the carrier peptide. The
experimental data were analyzed as correlation plots and
revealed a relationship between transfection efficiency and
parameters, including the presence of lytic and carrier pep-
tides, the number of lysine residues in the carrier molecule,
DNA dose, and zeta potential of the complex.
As part of the development of a novel gene delivery
system for the transfer of human growth hormone (hGH)
gene to muscle cells, a prototype peptide-based gene deliv-
ery system was tested in vitro. Transfection efficiency of a
peptide delivery system was assessed in 14-day myotubes
by quantitation of the levels of hGH secreted in the culture
medium.
MATERIALS AND METHODS
Preparation of the gene expression systems
Both the reporter gene expression system (CMV--gal), containing the
-galactosidase reporter gene driven by the cytomegalovirus (CMV) pro-
moter, and the therapeutic gene expression system (sk-hGH), containing
the human growth hormone gene (hGH) driven by the chicken skeletal-
actin (sk) promoter, were prepared, purified, and quality controlled at
GeneMedicine.
Peptide synthesis and purification
The carrier peptides GM204 (YKAK4WK), GM205 (YKAK5WK),
GM206 (YKAK6WK), GM207 (YKAK7WK), GM208 (YKAK8WK),
GM212 (YKAK12WK), and GM240 (YKAK40WK), and the amphipathic
peptide GM225.1 (GLFEALLELLESLWELLLEA) were synthesized by
the solid phase method developed by Merrifield (Barany and Merrifield,
1980), using fast HBTU/HOBT (HBTV, 2-(1H-benzotriazol-l-yl)-1,1,3,3-
tetramethyluroniumhexafluorophosphate; HOBT, N-hydroxybenzotria-
zole) coupling (Reid and Simpson, 1992) as described previously
(Gottschalk et al., 1996).
Both carrier and endosomolytic peptides were purified by reversed-
phase high-performance liquid chromatography (HPLC) (Hancock and
Sparrow, 1981, 1984). Carrier peptides were initially diluted in 1% triflu-
oroacetate (TFA) and loaded on a 2.5  25 cm Vydac C18 column
equilibrated in 0.1% TFA. The peptides were eluted using a linear gradient
from 0.1% TFA to 0.1% TFA with 10% 2-propanol at a flow rate of 20
ml/min. After elution, the purified peptides were collected, lyophilized, and
redissolved in MilliQ water.
GM225.1 was diluted in 0.1 M ammonium phosphate in 6 M guanidine
HCl (pH 6.7) and loaded onto a 2.5  25 cm Vydac C4 column equili-
brated in 0.01 M ammonium phosphate. The peptides were eluted using a
linear gradient from 0.01 M ammonium phosphate (pH 6.7) and 30%
2-propanol to 0.01 M ammonium phosphate and 50% 2-propanol at a flow
rate of 20 ml/min. After elution, peptide fractions were pooled, adjusted to
pH 8.0 with ammonium hydroxide, and desalted on a BioGel P-2 column
equilibrated in 0.1 M ammonium bicarbonate. The desalted peptide was
then lyophilized and redissolved in water. Dilute ammonium hydroxide
was added to maintain a pH of 7.5 to completely dissolve the peptide.
Peptide purity was evaluated by the following methods: 1) analytical
HPLC: for GM225.1, a linear gradient from 0% to 50% 2-propanol in 0.01
M ammonium phosphate at pH 6.8; for GM208, a linear gradient from 0%
to 10% 2-propanol in 0.1% TFA; 2) fast atom bombardment or electrospray
mass spectrometry; 3) amino acid analysis to verify composition; 4)
automatic amino acid sequencing; and 5) capillary electrophoresis.
Physicochemical characterization of peptide-
based gene delivery systems
Preparation of the peptide-based gene delivery system
Before the preparation of the peptide/plasmid complexes, the pH values of
all carrier and amphipathic peptides were measured. Titrations were per-
formed on peptide solutions in which there was a deviation greater than pH
7.0  1.0. Acetic acid was used to titrate basic solutions, and ammonium
hydroxide was used for acidic solution. The peptide solutions were titrated
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within the desired range near pH 7.0. The gene expression systems were
within the pH range 6.8–7.5. Plasmid samples were prepared in water or
0.5 mM HEPES at predetermined volumes, each in culture tubes (14-956-
3D; Fisher Scientific) at the appropriate DNA concentration. The carrier
peptide was added to the plasmids under constant vortexing. Typical
volume ratios of carrier peptide added to DNA solution were in the range
of 0.017–0.11. These samples were allowed to stand for 30 min to ensure
complete complexation between the plasmid and peptide carrier. After 30
min, the amphipathic peptide (GM225.1) was added to the carrier peptide/
plasmid colloidal suspension under vortexing. Volume ratios of amphi-
pathic peptide solution/(carrier peptide plus plasmid suspension) were in
the range of 0.007–0.022. No effect of volume ratios on hydrodynamic
diameter or transfection efficiency was observed under these experimental
conditions. All peptide/plasmid complexes were characterized for their
solution pH, hydrodynamic diameter, and zeta potential. pH values were
measured with a Ross combination electrode (no. 8103; Orion) and a pH
meter (no. 720A; Orion).
Photon correlation spectroscopy measurements
Particle sizing measurements were conducted on each peptide-based gene
delivery system to ensure that the complexes were self-assembled into
compact particles. Particle size was subsequently used to determine
whether cell transfection was influenced by this parameter. The particle
size of the complex was determined by photon correlation spectroscopy,
which computes the autocorrelation function of the intensity of light
scattered by the peptide/plasmid complexes. Light scattering data were
collected at a 90° angle for a period of 2 min for all formulations, using a
Coulter submicron particle analyzer (model N4MD; Coulter Electronics,
Hialeah, FL). Unimodal analysis was performed on each data set; here the
autocorrelation function was treated as a single decaying exponential with
a decay constant that is directly proportional to the diffusion coefficient
(Dtrans) of the complex. Particle size of the complex was determined from
the Stokes-Einstein relation
Dtrans kBT/3DH (1)
where kB is Boltzmann’s constant, T is the sample temperature,  is the
solution viscosity, and DH is the hydrodynamic diameter of the complex.
Transmission electron microscopy
The preparation and visualization of peptide/plasmid complexes utilized
for transmission electron microscopy (TEM) studies were performed as
described by Ma (1992). Briefly, carbon-coated 200-mesh copper grids
(Ted Pella, Redding, CA) were glow discharged for 90 s to render them
hydrophilic. One drop of the complex of the colloidal suspension was
deposited on the grids. Each grid was then stained with a drop of 1% uranyl
acetate solution (Ted Pella), and excess stain was removed after 30 s. The
grid was then allowed to dry for at least 20 min before TEM examination.
Electron micrographs were obtained at magnifications ranging from
28,000 to 55,000 on a JEOL microscope operating at 60 kV. Particle
sizes of the complexes were determined by comparing their outer diameters
with grid markings.
Electrophoretic light scattering measurements
Electrophoretic light scattering (ELS) measurements enable the determi-
nation of the zeta potential () of a particle, which is proportional to its
surface charge density. The zeta potential is defined as the electrical
potential between the shear plane surrounding the particle and the bulk
solution. ELS studies were performed on the peptide-based gene delivery
system to determine whether  of these particles influenced cell transfec-
tion. The  of the complex was determined by electrophoretic light scat-
tering with a Coulter DELSA 440 (Coulter Electronics). In the electro-
phoretic mobility cell, the complex was subjected to an alternating electric
field in constant current mode with a magnitude no greater than 0.2 mA at
25°C. Data collection was performed periodically at two different currents
to ensure that the measured zeta potentials were independent of the choice
of current. The light scattering intensity was collected at 8.6°, 17.1°, 25.6°,
and 34.2° angles over a minimum period of 30 s at a frequency of 500 Hz.
Doppler shifts () were calculated as a function of the time dependence of
scattered light intensity from the moving particle in the presence of the
alternating electric field. The relationship between the Doppler shift of
scattered light and electrophoretic mobility (U) of the mobile complex was
determined from the equation
U 2/EK cos  (2)
where E is the applied electric field, K is the magnitude of the scattering
vector, and  is the angle between the scattering vector and the direction
of migration of the complex. The  of the particle was determined from the
equation
  4U/	 (3)
where 	 is the dielectric constant of the solution.
Hemolysis assay for determination of lytic peptide activity
The assay used to determine hemolytic activity was modified from the
procedure of Gagne et al. (1994). Fresh blood was obtained from rats and
preserved in 0.38% sodium citrate to prevent clotting. Red blood cells
(RBCs) were obtained from whole blood by centrifugation in a clinical
centrifuge at 2500 rpm for 10 min. Upon removal of the supernatant, the
RBCs were washed with an equal volume of 1 phosphate-buffered saline
(PBS) (0.144 g/liter KH2PO4, 9.0 g/liter NaCl, 0.726 g/liter
NaH2PO47H2O). Appropriate dilutions of RBCs were made using 1 PBS
before placing 15-
l aliquots between the coverslip and hemocytometer.
RBCs were counted in the four corner and central squares in the two
complementary hemocytometer chambers. An average RBC count per
square was obtained and used to determine the number of cells per unit
volume.
For the hemolysis assay, stock solutions of 2% Triton X-100 and
GM225.1 were prepared separately in hemolysis buffer (150 mM NaCl, 20
mM Na citrate) at pH 5.0 and pH 7.4. In each well of a 96-well microtiter
plate, 100 
l of a stock solution was diluted with 100 
l of hemolysis
buffer at the same pH. Serial dilutions were performed on the solutions of
GM225.1 to investigate concentration effects on hemolytic activity. RBCs
were diluted to a final cell density of 1  108 cells/ml at the appropriate
pH, from which 100-
l aliquots were added to each well and allowed to
incubate at 37°C for 0, 30, 60, 120, and 180 min. After incubation, the
absorbance at 540 nm (A540) was measured for each sample with the EL
340 Microplate Reader (Bio-Tek Instruments, Winooski, VT). The lytic
activity was calculated as the A540 of the RBCs in the presence of peptide,
normalized between their A540 in the presence of Triton X-100 (100% lytic
activity) and their A540 in the absence of a lytic agent (0% lytic activity).
Separate normalization parameters were calculated at pH 5.0 and pH 7.4.
Circular dichroism studies of the lytic peptide structure
The conformational changes of GM225.1 were monitored using circular
dichroism (CD) spectroscopy as the peptide becomes lytically active in the
presence of lipid membranes. An Aviv 62A DS spectropolarimeter (Aviv,
Lakewood, NJ) was used for the collection of CD spectra. To fully
characterize this structural transition, CD spectra were obtained in the
presence and absence of liposomes as a function of peptide concentration
and pH. Before spectral data were collected, the sample chamber was
flushed with nitrogen, and the sample cell was incubated at 37°C. Extruded
liposomes (DH  100 nm) containing 4 
M total lipid in a 1:1 mole ratio
of N-[2,3-(dioleyloxy)propyl]-N,N,N-trimethylammonium chloride
(DOTMA) and 1,2-dioleoyl-3-phosphatidylethanolamine (DOPE) were
then incubated with GM225.1 at 37°C for 10 min. Peptide concentrations
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used for these experiments were in the range of 0.01–0.60 mg/ml (4.3–260

M). To distinguish pH and liposome effects, GM225.1 was incubated at
pH 5.0 and pH 7.4 in the presence and absence of liposomes. After
incubation, the samples were scanned three times from a wavelength of 290
nm down to 195 nm. The instrument settings include a 1-nm bandwidth and
a sampling time of 10 s at 1-nm intervals. Ellipticity data (d, in units of
degrees) were collected on a 7100/66 PowerMac with the software appli-
cation CDStar b97 (Aviv). The data were then baseline corrected and
converted to mean molar ellipticity per residue (mrd), using the equation
mrd 100*d/C*I*nr (4)
where C is the molar concentration of the peptide, l is the cell pathlength,
and nr is the number of amino acid residues per peptide. The factor of 100
was used to convert molar concentration into dmole/cm3, so that mrd is
expressed in its proper units {deg*cm2/(dmol*residue)}. The wavelength
dependence of mrd was then used to monitor any changes in the confor-
mation of GM225.1.
Cell transfection experiments
RAW264.7 mouse macrophages and HIG-82 rabbit synoviocytes were
purchased from the American Type Culture Collection (ATCC). The C2C12
mouse myoblasts were a kind gift from Dr. Robert Schwartz (Department
of Cell Biology, Baylor College of Medicine). Cells were plated at an
initial density near 100,000 cells/well in 20-mm tissue culture plates. Both
myoblasts and macrophages were cultured in Dulbecco’s modified Eagle
medium (DMEM) (Gibco BRL/Life Technologies, Gaithersburg, MD)
with 10% fetal bovine serum (FBS), and the HIG-82 cells were cultured in
Ham’s F12 medium with 10% FBS. The culture medium was changed
every 48 h until the transfection experiments.
Preparation of C2C12 myotubes
C2C12 myoblasts were plated at a density near 100,000 cells/well in 20-mm
tissue culture plates (24 wells/plate) in DMEM supplemented with 10%
FBS. After reaching 100% confluency, the medium was changed to
DMEMwith 2% horse serum. The culture medium was then changed every
48 h for 14 days until myotube formation was complete. Before transfec-
tion, the medium was changed back to DMEM with 10% FBS. All media
used for myotube preparation contained 100 units/ml penicillin and 100

g/ml streptomycin.
Cell transfection using the peptide/DNA delivery complex
DNA concentrations were prepared in either water or 0.5 mM HEPES at
volumes of 2 ml each in Fisher culture tubes at a final concentration of
33–99 
g/ml. An aliquot of carrier peptide was added to plasmids at
lysine:phosphate ratios ranging from 0:1 to 6:1. The amphipathic peptide
GM225.1 was added to the complex at a glutamate:DNA phosphate ratio
of 1:1. The carrier peptide/plasmid/lytic peptide complexes were allowed
to stand for 30 min before transfection.
One hour before transfection, the cell line was incubated in cell culture
medium containing 10% FBS. Three hundred microliters of the colloidal
suspension of the complex was added to each well and allowed to incubate
for 5 h at 37°C. Afterward, 1 ml of the cell culture medium in 10% FBS
was added to each well.
X-Gal staining for visualization of -galactosidase activity
Cells were harvested 2 days after transfection, washed twice with PBS, and
fixed for 15 min at 4°C in a solution containing 1% glutaraldehyde, 100
mM sodium phosphate buffer (PBS, pH 7.0), and 1 mM MgCl2. This was
followed with repeated washings in PBS and incubation at 37°C for 1 h in
a staining solution containing 0.2% X-Gal, 10 mM sodium phosphate
buffer (pH 7.0), 150 mM NaCl, 1 mM MgCl2, 3.3 mM K4Fe(CN)63H2O,
and 3.3 mM K3Fe(CN)6. After incubation, the staining solution was re-
moved, and the cells were washed with PBS. Transfected cells were
identified by their blue color with a phase-contrast microscope (Zeiss,
IDO3).
Chemiluminescence assay for quantitative
transfection analysis
Quantitation of the transfection efficiency was performed with the Galacto-
Light chemiluminescent reporter assay kit (Tropix). Briefly, cell extracts
were prepared by adding 100 
l of lysis solution containing 100 mM
potassium phosphate (pH 7.8), 0.2% Triton X-100, and 1 mM dithiothre-
itol. Cells were then detached from the wells, transferred to a microfuge
tube, and centrifuged for 10 min at 4°C to pellet any debris.
Cell extracts (5–20 
l) were mixed with 200 
l reaction buffer (100
mM sodium phosphate (pH 8.0), 1 mMmagnesium chloride) and incubated
at room temperature for 2 h. Samples were then mixed with 300 
l of
accelerator (luminescent reagent), and -galactosidase activity was mea-
sured as a function of luminescence with a Lumat LB 9501/16 luminometer
(EG&G Berthold).
Analysis of media for the presence of human
growth hormone
After transfection with the peptide/sk–human growth hormone complex,
the cell culture medium for the C2C12 myotubes was harvested at 24-, 48-,
72-, and 96-h time points for detection of both human growth hormone
(hGH) and total protein. As a control, some myotubes were also transfected
with the peptide/CMV--gal complex. These cells were harvested 2 days
later to measure transfection efficiency with the chemiluminescence assay
described above.
The hGH 100 kit (Nichols Institute Diagnostics) was used for the
detection of hGH. This kit utilizes a radioimmunoassay that incorporates
two monoclonal antibodies that have a high affinity for hGH. Each of the
two antibodies (Ab1 and Ab2) are specific for different epitopes on the
hGH protein and bind independently at their respective sites to form a
sandwich complex, Ab1-hGH-Ab2. One of the antibodies is coupled to
biotin (biotin Ab1), whereas the other is radiolabeled (Ab2*) with 125I
(courtesy of Nichols Institute Diagnostics, San Juan Capistrano, CA).
Avidin beads are then added to the complex solution to form the complex
(avidin bead)-(biotin Ab1)-hGH-Ab2*, which presents, after repeated
washings, a radioactivity that is directly proportional to the amount of
hGH. The radioactivity bound to the avidin bead was measured over a
period of 1 min in a gamma counter and calibrated against a series of
raidolabeled hGH standards.
Quantitation of total protein in each cell extract
Total protein from each cell extract was determined using the Coomassie
Plus Protein Assay (Pierce), which measures the increase in absorbance at
595 nm that occurs when Coomassie Blue G-250 binds to protein in acidic
solution. The assay was calibrated by measuring the absorbance at 595 nm
of protein concentrations of bovine serum albumin (BSA) standards
(Pierce) ranging from 1 to 25 
g/ml.
RESULTS
DNA condensation was observed in the presence of each of
the oligolysine peptides, GM208–GM240, when the total
concentration of lysine exceeded that of the DNA phos-
phates. PCS studies show an increased photon count rate
and a reduced decay constant in the autocorrelation func-
tion, as well as a decreased hydrodynamic diameter and
polydispersity index. These observations are consistent with
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previous studies on condensed DNA using light scattering
techniques (Bloomfield et al., 1992; Ma and Bloomfield,
1994; Post and Zimm, 1982a). Near equimolar concentra-
tions of lysine:phosphate, there is a tendency toward aggre-
gation, presumably due to reduced polyelectrolyte repulsion
upon charge neutralization. Such effects are most noticeable
at higher DNA concentrations and lower charge ratios.
A representative plot from the PCS studies is illustrated
in Fig. 1, which shows the correlation between particle size
and DNA concentration for a GM208/DNA complex in the
presence of excess positive charge (3/1 GM208 lysines/
DNA phosphates). Fig. 1 reveals that the weighted-average
hydrodynamic diameter of the complex increases with DNA
concentration. Furthermore, the size distribution becomes
more heterogeneous, indicating a potential limitation on the
amount of DNA that can be compacted into a condensed
particle. At each DNA concentration, the particle size is
stable for at least 116 h.
Transmission electron micrographs confirm the particle
size of the GM208/DNA complexes that were characterized
by photon correlation spectroscopy. Fig. 2 A shows sample
transmission electron micrographs of these complexes,
which have a size range of 30–80 nm (outer diameter) at a
plasmid concentration of 20 
g/ml and a charge ratio of
three lysines per DNA phosphate. Their hydrodynamic di-
ameter, measured by photon correlation spectroscopy, is
30–60 nm. The majority of the GM208/DNA complexes
have a toroidal morphology, whereas a proportionately
smaller number of rods and spheres are also observed. This
is consistent with observations of DNA condensation in the
presence of polyamines (Chattoraj et al., 1978; Gosule and
Schellman, 1976; Wilson and Bloomfield, 1979), poly-L-
lysine (Wagner et al., 1991), and other macromolecules
(Ghirlando et al., 1992; Laemmli, 1975). Upon incorpora-
tion of GM225.1, the peptide/DNA complexes are mostly
spherical and are 0–50% larger than their GM208/DNA
counterparts (see Fig. 2 B).
Results from the hemolysis assay (see Fig. 3) show that at
concentrations between 3.5 and 104 
g/ml, the lytic activity
of GM225.1 is comparable to Triton X-100 after a 1-hour
incubation period at pH 5.0. Lytic activity at pH 7.4 is near
zero at all peptide concentrations, except near 566 
g/ml,
which is still 18% relative to Triton X-100. A pH-depen-
dent profile of the number of lysed RBCs (see Fig. 4) shows
that the lytic activity of GM225.1 decreases dramatically
when the pH is raised from 5 to 5.5, and is near zero at
pH  6.0.
Fig. 5 shows representative plots from pH-dependent CD
studies on GM225.1 in the presence (Fig. 5, A and B) and
absence (Fig. 5 C) of preformed liposomes. These results
FIGURE 1 Particle sizing data of GM208/DNA complexes as a function
of DNA concentration and time. E, Time measurement taken at 0 h; ,
time measurement taken at 116 h.
FIGURE 2 Peptide/plasmid particles observed by TEM. (A) Plasmid/
GM208 particles prepared at a 1/3 charge ratio (	/
) and a plasmid
concentration of 20 
g/ml. Original magnification, 70,000. (B) Plasmid/
GM208/GM225.1 particles prepared at a 1/3/1 charge ratio (	/
/	) and
a concentration of 20 
g/ml DNA. Original magnification, 50,000.
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indicate that GM225.1 undergoes a significant conforma-
tional transition in the presence of the liposomes as the pH
is lowered from 7.4 to 5.0. This transition results in a
significant change in molar ellipiticity at 210 nm, which is
indicative of a loss in the -helicity of the endosomolytic
peptide. The conformational transition was observed at a
GM225.1 concentration of 0.10 and 0.17 mg/ml, but not at
0.60 mg/ml (Fig. 5 B). In addition, a comparison of Fig. 5,
A and C, illustrates that the liposomes are required to induce
the conformational change.
The effects of a peptide-based gene delivery system on
the transfection of CMV–-Gal into 14-day C2C12 myo-
tubes are shown in Fig. 6. Transfection efficiency, as mea-
sured in terms of relative light units (RLU) per microgram
of protein, is dramatically enhanced by both carrier and
amphipathic peptides, relative to either peptide or plasmid
alone. A visualization of the 14-day C2C12 myotubes, after
transfection with the peptide/plasmid complex, is illustrated
in Fig. 7. -Galactosidase activity, which is proportional to
the number and intensity of blue cells, permeates the cul-
tured myotubes and is dipersed along the tubule striations.
FIGURE 3 Hemolytic activity of the endoplasmic peptide. —E—,
GM225.1, as a function of concentration at pH 5.0; , 7.4. Incubation
time, 1 h at 37°C. From Rolland (1996).
FIGURE 4 Red blood cell membrane lysis by the endoplasmic peptide
GM225.1 as a function of concentration at pH. Reaction conditions include
25 
l peptide at 1 
g/
l added to 75 
l red blood cells. Incubation time,
1 h at 37°C.
FIGURE 5 CD spectra of the endosomolytic peptide GM225.1 in the
presence and absence of liposomes. Samples were incubated for 10 min at
37°C before spectral measurements.E, pH 5.0;F, pH 7.4. (A) 43 
M (0.10
mg/ml) GM225.1 plus 4 
MDOTMA:DOPE (1:1 mole ratio). (B) 261 
M
(0.60 mg/ml) GM225.1 plus 4 
MDOTMA:DOPE (1:1 mole ratio). (C) 43

M (0.10 mg/ml) GM225.1.
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No such activity is observed in the absence of either the
carrier or amphipathic peptide.
To better understand the relationship between the physi-
cal properties of the complexes and their ability to affect
transfection efficiency in vitro, we have performed a study
that compares the particle size, plasmid dose, peptide/plas-
mid charge ratios, and zeta potential of the complex in
suspension with transfection efficiency. An examination of
physical and transfection data in Table 1 reveals that trans-
fection efficiency in C2C12 myotubes increases with plas-
mid dose and positive zeta potential. In addition, Fig. 6
indicates that transfection efficiency is greatly enhanced by
the presence of both endosomolytic and carrier peptides, the
latter of which maintain colloidal stability of the particle.
Thus, in the presence of endosomolytic and carrier peptides,
transfection efficiency is influenced by two parameters,
which can be combined into a physical index factor (I),
defined by the equation
I m*DNA (5)
where mDNA and  are the plasmid dose and zeta potential,
respectively. These results suggest that in addition to an
adequate carrier and amphipathic agent, a sufficient amount
of plasmid and high cell surface affinity are necessary for an
effective gene delivery system.
To validate the use of Eq. 5 as a predictor of transfection,
correlation plots were constructed between the physical
index factor and the observed in vitro transfection effi-
ciency, as exemplified in Fig. 8. This plot reveals a corre-
lation coefficient of 0.96 between the physical index factor
and transfection efficiency. Similar correlation plots were
made in five separate studies utilizing three separate cell
lines, the results of which are shown in Table 2. The
correlation coefficients between the physical index factor
and transfection efficiency range from 0.81 to 0.98.
To better understand how different peptides can influence
gene delivery, we investigated the effects of the number of
lysine residues in the carrier peptide on transfection effi-
ciency. Fig. 9 A shows the results of transfections in C2C12
myotubes using carrier peptides GM204-GM208, GM212,
and GM240, corresponding to 4–8, 10, 12, and 40 core
lysine residues, respectively. Maximum transfection occurs
for complexes prepared with GM206-GM208, whereas
transfection is attenuated when complexes are prepared with
GM204-GM205 and GM240. Enhanced transfection effi-
ciency is seen with GM205 as compared to GM204 at
higher carrier peptide/plasmid ratios, although at much
FIGURE 6 In vitro transfection of 14-day C2C12 myotubes: DNA, 20 
g
plasmid/well; GM208, plasmid/GM208, 1/3 (	/
) charge ratio, 20 
g
plasmid/well; GM225.1, plasmid/GM225.1, 1/1 (	/	) charge ratio, 20 
g
plasmid/well; GM208 
 GM225.1, plasmid/GM208/GM225.1, 1/3/1 (	/

/	) charge ratio, 20 
g plasmid/well.
FIGURE 7 X-Gal staining of 14-day C2C12 myotubes after transfection
with the peptide-based gene delivery complex containing CMV--gal. (A)
Cells with background -galactosidase activity. (B) Cells transfected with
plasmid/GM208/GM225.1, 1/3/1 charge ratio, 20 
g plasmid/well. Posi-
tive cells for -galactosidase activity are stained dark blue.
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lower levels than GM206-GM208. Thus, among the lower-
molecular-weight carrier peptides, enhanced transfection
efficiency is observed with each additional lysine residue.
Similarly, an inspection of the sizing data in Fig. 9 B reveals
that each additional lysine residue enhances particle stabil-
ity of the formulated complex, as measured by a reduction
in polydispersity and hydrodynamic diameter. The relation-
ship between transfection efficiency and enhanced particle
stability (Scarrier) created by additional lysine residues can be
modeled by the expression
Scarrier 1/1 k1expk2n (6)
where k1 is the minimum number of lysine residues required
to enhance transfection efficiency via particle stabilization,
k2 is the enhanced transfection efficiency created by each
additional lysine residue, and n is the number of lysine
residues in the carrier peptide. This equation, which is
normalized relative to maximum transfection efficiency,
puts a constraint on the minimum number of lysine residues
required for maximum transfection efficiency.
Fig. 9 A also shows that increasing the number of lysine
residues on the carrier peptide can reduce transfection effi-
ciency once this number goes beyond a certain limit. Cell
toxicity, as indicated by observed cell death, suppressed
protein levels, and reduced cellular metabolism, occurs in
C2C12 myotubes after they are transfected with a peptide/
plasmid complex that contains GM240. When compared
with other carrier peptides, GM240 typically reduces cellu-
lar protein production by a factor of 2–4. Similar effects of
cytotoxicity have been observed when polylysine, the chain
length of which is greater than 20 residues, was added to
T24 cells (Deshpande, 1996), or when a 100-mer of poly-
lysine was used to transfect HepG2 cells (L. C. Smith et al.,
unpublished data). The relationship between transfection
TABLE 2 Correlation between the physical index factor (I)
and the transfection efficiency of peptide-based gene delivery
systems
Cell line Cell type Correlation coefficient
C2C12 14-day mouse myotubes 0.93–0.96
HIG82 Rabbit fibroblasts 0.98
RAW264 Mouse macrophage 0.81–0.90





DNA dose per well
(




1 1/0/1 10 	42 N/A 0 0
2 1/0/1 20 	62 N/A 0 0
3 1/0/1 30 	70 N/A 0 0
4 1/3/0 10 30 153 7339 0
5 1/3/0 20 29 133 15594 0
6 1/3/0 30 33 148 26600 0
7 1/6/0 10 35 127 1763 0
8 1/6/0 20 42 150 15565 0
9 1/6/0 30 67 156 0 0
10 1/3/1 10 35 187 78002 350
11 1/3/1 20 41 169 219956 820
12 1/3/1 30 39 173 309946 1170
13 1/3/1 10 41 167 39895 410
14 1/3/1 20 40 189 181314 800
15 1/3/1 30 40 202 273326 1200
16 1/6/1 10 40 142 151580 400
17 1/6/1 20 41 172 290068 820
18 1/6/1 30 41 172 386163 1230
19 1/6/1 10 40 153 125785 400
20 1/6/1 20 35 242 299749 700
21 1/6/1 30 36 222 361850 1080
22 Control* N/A N/A N/A 197 N/A
*Untransfected cells.
FIGURE 8 Correlation analysis between the physical index factor (I 
mDNA*) and the transfection efficiency (RLU/
g protein) in C2C12
myotubes.
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efficiency and cell toxicity (Tcarrier) induced by additional
lysine residues can be described by the inverted sigmoid
function
Tcarrier 1 1/1 k3expk4n (7)
where k3 is the minimum number of lysine residues required
to reduce transfection efficiency via cell toxicity, k4 is the
diminished transfection efficiency created by each addi-
tional lysine residue, and n is the number of lysine residues
in the carrier peptide. Equation 7, which is also normalized
relative to maximum transfection efficiency, places an up-
per limit on the number of lysine residues that can be
incorporated into the carrier peptide.
To predict the optimal number of core lysines, the effects
of particle stabilization and cell toxicity on transfection
efficiency have been modeled as a linear combination of




which ensures upper and lower boundary limits on the size
of the carrier peptide and guarantees an optimal number of
core lysines for maximum transfection. The predicted trans-
fection efficiency from this model is shown in Fig. 10. A
correlation analysis between the predicted transfection effi-
ciency in Fig. 10 and the observed transfection efficiency
(Fig. 9 A) as a function of the number of core lysine residues
in the carrier peptide is shown in Fig. 11. This result
suggests that for these peptides, the number of lysine resi-
dues on the carrier peptide influences transfection efficiency
through at least two factors: instability of the DNA-peptide
complex for a small number of lysine residues and cytox-
icity generated by a large number of lysine residues.
The effect of utilizing a peptide-based gene delivery
system in transferring the hGH gene to 14-day C2C12 myo-
tubes is illustrated in Fig. 12. This result shows an increased
daily production of hGH to 22 ng/ml after 96 h if the
medium is replaced every 24 h. It is also observed that hGH
production reaches a maximum for a dose of 20 
g DNA/
well. This observation is in contrast to -galactosidase
expression, which increases continuously to the highest
dose of DNA added to the well. One hypothesis is that there
may be a feedback inhibition mechanism created as a result
of expression of the hGH gene. Another possibility is that
the limitations of expression may be a function of the
different control elements associated with the two con-
structs. In either case, this observation implies that Eq. 5
may require an upper limit constraint on the DNA dose. A
similar possibility exists for an upper limit on zeta potential
in effecting transfection efficiency.
DISCUSSION
A peptide-based gene delivery system has been shown to
require both carrier and amphipathic peptides for effective
in vitro cell transfection. The former provides lysine-medi-
FIGURE 9 A comparison of the mean diameter of plasmid/peptide par-
ticles and transfection efficiency in C2C12 myotubes as a function of the
number of lysine residues in the carrier peptide. (A) Transfection data. (B)
Particle sizing data. From left to right: vertical stripes, GM204; horizontal
stripes, GM205; angled stripes, GM206; solid black, GM207; Cross-
hatching, GM208; solid white, GM212; dotted, GM240. * indicates broad
size distribution.
FIGURE 10 Predicted transfection efficiency in C2C12 myotubes as a
function of the number of lysine residues in the carrier peptide, as defined
in Eq. 8. From left to right: vertical stripes, GM204; horizontal stripes,
GM205; angled stripes, GM206; solid black, GM207; cross-hatching,
GM208; dotted, GM240.
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ated charge neutralization of the DNA phosphate residues,
which leads to plasmid condensation and stabilization of the
resulting complex. This complex forms small particles (DH
 150 nm) at DNA concentrations as high as 400 
g/ml,
which are stable in water over a period of several days.
Complex stability and transfection efficiency also depend
on the number of lysine residues present in the carrier
peptide, which must be greater than four, as suggested by
particle size measurements and transfection studies in C2C12
myotubes.
Previous studies (Bloomfield et al., 1980; Wilson and
Bloomfield, 1979) have indicated that effective condensa-
tion requires a condensing agent with a net charge that is
only greater than 2 (in one instance, it has been shown that
a complex involving the transition metal Mn2
 is also an
effective condensing agent; Ma and Bloomfield, 1994).
These studies were performed at low DNA concentrations
(20 
g/ml), and we observe similar results under similar
conditions. However, we observe an increase in particle size
and polydispersity at higher DNA concentrations. This im-
plies that the condensate may become increasingly unstable.
Normally, we perform transfection studies at DNA concen-
tration ranges from 33 to 100 
g/ml. At these concentra-
tions, a greater number of charged residues per carrier
peptide may be required to maintain particle stability.
As an alternative explanation, the higher charge require-
ment on the carrier peptide may be necessary at higher
plasmid concentrations to maintain the gene delivery com-
plex in its activated state. Previous studies (Arscott et al.,
1995) have shown that different complex morphologies can
be obtained when the DNA concentration is raised. The
unique morphologies formed at elevated plasmid concen-
trations can lead to complexes that have lower transfection
activities. A more highly charged peptide can provide a
barrier to the formation of these different structural states
and maintain transfection integrity. These hypotheses are
consistent with Fig. 9, which shows that a reduction in
particle size occurs simultaneously with enhanced transfec-
tion efficiency when the number of lysine residues on the
carrier peptide is greater than four.
GM225.1, which was designed to induce a pH-dependent
lytic effect on biological membranes, is expected to be
required in the peptide/plasmid complex for endosomal
release after particle uptake via endocytosis. Evidence for
an endosomolytic effect of GM225.1 can be observed not
only by the in vitro transfection assays performed in this
study, but also by the results of the hemolytic assays that
demonstrate a pH-dependent lysis of red blood cell mem-
branes. One interesting observation from the hemolytic as-
says is that when the concentration of GM225.1 is in-
creased, the lytic activity increases sharply at low
concentrations, reaches a maximum, and then decreases to
almost zero. One explanation of this observation is that the
increase in the concentration of GM225.1 eventually leads
to aggregate formation that inactivates this peptide.
GM225.1 tends to aggregate readily, and the presence of 6
M guanidine HCl is required to prevent the formation of
multimeric peptide structures (J. T. Sparrow and L. C.
Smith, unpublished data).
The structural properties of GM225.1 are comparable to
those of other lytic peptides derived from the influenza virus
hemagglutinin (HA) (Doms et al., 1991; Ojcius and Young,
1991; Plank et al., 1994; Ramalho-Santos et al., 1993;
Wagner et al., 1992; Wharton et al., 1988) and the GALA
peptide (Parente et al., 1990a,b; Subbarao et al., 1987). Such
properties include an -helical structure, as evidenced by
circular dichroism, and the N-terminal hydrophobic GLF
motif that is considered to enhance membrane insertion
(Doms et al., 1991; Ojcius and Young, 1991; Plank et al.,
1994; Ramalho-Santos et al., 1993; Wagner et al., 1992).
Interestingly, our CD studies reveal that the -helical struc-
ture of GM225.1 is significantly reduced at lower peptide
concentrations, in the presence of cationic liposomes, and at
a lowered pH of 5.0. These conditions are consistent with
FIGURE 11 Correlation analysis between the observed transfection ef-
ficiency (Fig. 9 A) and that predicted by Eq. 8 (Fig. 10). The standard
deviation is shown for the transfection experiment (n  3).
FIGURE 12 Production of human growth hormone (hGH) as a function
of DNA dose and media replacement every 24 h after transfection with
plasmid/GM208/GM225.1 complexes (1/3/1 	/
/	). Gray column, me-
dia replacement at 48 h; white column, 72 h; black column, 96 h.
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those associated with increased hemolytic activity, which
suggests that the observed structural transition leads to an
activated state of GM225.1. Although this transition is most
pronounced in the presence of cationic liposomes, similar
perturbations of the CD spectra can be observed at pH 5.0,
when low concentrations of GM225.1 (0.1 mg/ml) are
incubated with anionic liposomes.
Finally, GM225.1 is designed with distinct hydrophobic/
hydrophilic faces in which the latter subtends an angle
greater than 120°, which has been suggested to be required
for membrane insertion (Tytler et al., 1993). This is most
aptly illustrated in a helical wheel diagram of GM225.1,
which shows the hydrophobic and hydrophilic portions of
the peptide chain (Fig. 13).
We have correlated several physical properties of the
complex with in vitro transfection efficiency. There is a
linear correlation between combinations of zeta potential,
DNA dose, the presence of carrier and lytic peptides, and
transfection efficiency. These observations have been made
in different cell lines, including macrophages, synoviocytes,
and myotubes. The physical index factor (I), which provides
a mathematical description of the physical properties re-
quired for transfection, illustrates a need for an effective
DNA dose and a requirement for cell surface affinity (as
measured by the  potential). The incorporation of the 
potential into the physical index factor is essential for the
prediction of in vitro transfection efficiency, because it
provides a real measure of the affinity of the gene delivery
complex for charged cell surfaces. One may argue that the
concentration of carrier peptide in solution may serve as a
substitute for the  potential in predicting affinity between
the cell surface and the gene delivery complex. However,
we find experimentally that the solution concentration of
carrier peptide is inadequate in predicting transfection effi-
ciency. This occurs because the number of carrier peptides
incorporated into the gene delivery complex is influenced
by factors other than the solution concentration of carrier
peptide. Such factors include counterion saturation of the
DNA phosphates, misalignment of the charge spacings be-
tween the carrier peptide and plasmid DNA, and sequestra-
tion of the carrier peptide by the endosomolytic peptide.
Because the number of peptides incorporated into the plas-
mid can be influenced by several different factors, the zeta
potential is a better indicator of transfection efficiency,
because it absorbs all of these factors into one experimen-
tally measurable parameter.
The requirement of a carrier peptide in the complex can
be defined more specifically as a requirement for a carrier
peptide with a specific number of lysine residues. Although
we have not ruled out other factors, such as excessive
complex stability, our experimental evidence suggests that
the ideal number of lysine residues depends upon optimi-
zation between complex stability and minimum cell toxic-
ity. The requirement of a carrier peptide with a specific
number of lysine residues places an additional constraint on
the physical properties necessary for an effective peptide-
based gene delivery system. When this constraint, as de-
fined in Eq. 8, is incorporated into Eq. 5, the following
relationship is obtained:
I S*carrierT*carrierm*DNA (9)




The results from Eq. 10 are still by no means complete.
However, it does provide an initial understanding between
the physical properties of the particle and transfection
efficiency.
To qualify the use of the peptide/plasmid complex as a
therapeutic gene delivery system, we have shown its capac-
ity to deliver the therapeutic human growth hormone gene
to 14-day C2C12 myotubes. The successful delivery of this
gene to well-differentiated muscle cells and the prolonged
gene expression observed to increase over a 4-day period
illustrate the potential usefulness of employing peptide-
based delivery systems for gene therapy.
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